More information: Eric J. Jaehnig et al, Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers, Cell Reports Medicine (2025).

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors ...

Overall, women who have HR+ and HER2- breast cancer do best. But in the later stages, those who have the HER2+ type have better survival rates than those with HER2-.

HR positive, HER2 negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers. 1 Despite being classified as HER2 negative, many of these tumors still ...

A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. npj Breast Cancer, 2025; 11 (1) DOI: 10.1038/s41523-025-00742-x ...

Key Takeaways The HEROES trial explores de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using the Signatera test to guide treatment decisions. The trial aims to enroll 170 ...

In the phase 3 VERITAC-2 trial (ClinicalTrials.gov Identifier: NCT05654623), study participants with ER+/HER2- advanced breast cancer (N=624) were randomly assigned to receive either oral ...

SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that the first patient has ...

Key Takeaways Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% ...

HER2 overexpression or gene amplification rates range from 4% to 5% for intrahepatic cholangiocarcinoma, 17% to 19% for extrahepatic cholangiocarcinoma, and 19% to 31% for gallbladder cancer.

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron ...

Cancer can also result when cells accidentally make extra copies of the DNA instructions that code for the normal version of HER2 and express higher levels of the protein on their surfaces.